HDAC inhibitors in liver cancer: which route to take?

Expert Rev Gastroenterol Hepatol. 2019 Jun;13(6):515-517. doi: 10.1080/17474124.2019.1605289. Epub 2019 Apr 17.
No abstract available

Keywords: Hepatocellular carcinoma; drug combination; epigenetics; histone acetylation; histone deacetylase inhibitor.

Publication types

  • Editorial

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Carcinoma, Hepatocellular / drug therapy*
  • Carcinoma, Hepatocellular / genetics
  • Carcinoma, Hepatocellular / mortality
  • Carcinoma, Hepatocellular / pathology
  • Clinical Decision-Making
  • Disease Progression
  • Epigenesis, Genetic / drug effects*
  • Histone Deacetylase Inhibitors / adverse effects
  • Histone Deacetylase Inhibitors / therapeutic use*
  • Humans
  • Liver Neoplasms / drug therapy*
  • Liver Neoplasms / genetics
  • Liver Neoplasms / mortality
  • Liver Neoplasms / pathology
  • Patient Selection
  • Treatment Outcome

Substances

  • Histone Deacetylase Inhibitors